Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO)
In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) with a $3.00 price target.
Cero Therapeutics Holdings Inc. (CERO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 15,600 | $227,760 | 0% | |
| 2. | Citadel Investment Group Ken Griffin | 810.9 | $11,839 | 0% | |
| 3. | 14,795.65 | $3,773 | 0% | ||
| 4. | 5,437.05 | $1,577 | 0% | ||
| 5. | 5,437.5 | $1,577 | 0% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.06 | 2,998,908 | $179,934.48 | 13,005,169 | 2024-12-13 | Filing | |
| $0.07 | 1,614,541 | $113,017.87 | 16,004,077 | 2024-12-12 | Filing | |
| $0.08 | 1,343,801 | $107,504.08 | 17,618,618 | 2024-12-11 | Filing | |
| $0.09 | 1,570,947 | $141,385.23 | 18,962,419 | 2024-12-10 | Filing | |
| $0.11 | 850,543 | $93,559.73 | 20,533,366 | 2024-12-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,000 | $160,600 | 0% | |
| 2. | 3,716.05 | $54,254 | 0% | |
| 3. | 2,134.35 | $31,162 | 0% | |
| 4. | 1,105.1 | $16,134 | 0.01% | |
| 5. | 845.85 | $12,349 | 0% |
News See All
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial
CERo Therapeutics Holdings, Inc.